Last reviewed · How we verify
Lipidem
At a glance
| Generic name | Lipidem |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The HOME Study (HPN With OMEGA-3) (PHASE4)
- Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants (PHASE2)
- Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function (PHASE3)
- A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer (PHASE2)
- Safety and Efficacy of Longterm HPN With Two Lipid Emulsions (PHASE4)
- The Effect of Fish Oils on Human Hepatic Colorectal Metastases (PHASE2)
- Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipidem CI brief — competitive landscape report
- Lipidem updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI